Why the study?
SARS-CoV-2 requires ACE2 for cellular entry, raising concern that commonly used ACEIs and ARBs could affect infectivity and disease progression by altering ACE2 expression.
Do ACEIs and ARBs affect SARS-CoV-2 infectivity and COVID-19 disease progression by altering ACE2 expression?
Do ACEIs and ARBs affect SARS-CoV-2 infectivity and COVID-19 disease progression by altering ACE2 expression?
This review highlights the theoretical interactions between renin-angiotensin system inhibitors and ACE2, the cellular entry receptor for SARS-CoV-2, emphasizing the need for clinical data to guide the management of patients on these medications during the COVID-19 pandemic.
Clinicians should not alter ACEI/ARB therapy on theoretical ACE2 grounds in COVID-19; leaves open effects on infectivity and lung injury.
The coronavirus disease 2019 (COVID-19) is the third major coronavirus outbreak of this century. Its aetiological agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), requires angiotensin converting enzyme 2 (ACE2) for cellular entry. The commonly used angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could affect SARS-CoV-2 infectivity and may alter COVID-19 disease progression by altering ACE2 expression. Current evidence of ACEI/ARB-ACE2 interaction as well as the effects of ACEIs/ARBs on viral-associated acute lung injury is summarized and discussed in this review. This review assesses the evidence gathered so far and highlights the research that needs to be done to help inform clinical decision making.
No takes yet. Share an insight, caveat, or question.
Siri‐Angkul et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: